Search Results

Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation System, announced the completion of the 100th implant of its Neuspera System as part of the SANS-UUI Phase II clinical trial.

Neuspera Medical, Inc. today announced it has completed patient enrollment and implant procedures for the pivotal clinical trial (SANS-UUI) of its Neuspera System, a discreet, minimally invasive implant designed to provide patients personal control and relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB).

Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system.

Neuspera® Medical announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer.

Neuspera® Medical today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI).

Neuspera Medical Inc. today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures.